Previsão

O preço-alvo médio dos analistas é € 99,75 (-21,75%). A mediana é € 105,62 (-17,14%).

Comprar	8
Manter	16
Vender	5

Notícias Ir para o feed de notícias

Moderna recovers from selling pressure thanks to cancer vaccine pipeline and approvals

Moderna shares rose about 7.5% in the morning to $146.84, recovering markedly from sell‑offs that had pushed the stock below its 52‑week high. Drivers include a reassessment of the previously negative view from Rothschild & Co Redburn, the Phase‑3 success of the personalized cancer vaccine Intismeran Autogen (together with Merck), and recent US approvals for updated COVID‑19 vaccines and the flu vaccine mFLUSIVA. Additional tailwinds come from a raise by Argus (price target $180), the upcoming presentation at the Morgan Stanley Global Healthcare Conference, and a positive market environment. » Mais em de.investing.com
Moderna: analysts dampen euphoria after rally around personalized cancer vaccine

After positive results with a personalized cancer vaccine, Moderna shares jumped, but Berenberg keeps a "Hold" rating and raises the price target to $100 while still seeing about 25% downside. The bank models a 95% chance of approval in melanoma and at most $3.5 billion in sales, but warns of missing detailed efficacy data and immature overall survival. Transferability of the effects to other cancer types is uncertain, and the recent rally was also boosted by short-covering; Moderna now needs to provide further details. » Mais em deraktionaer.de
Moderna shares: about 70% loss five years after purchase

Five years ago the Moderna share was trading at $449.38; on Sept. 9, 2026 it closed at $135.61. A $1,000 investment at that time would therefore have fallen to about $301.77, a loss of 69.82%. The market value of all Moderna shares was most recently around $55.90 billion; stock splits and dividends were not taken into account in the calculation. » Mais em finanzen.net

Dividendos históricos Dividendos

Todos os indicadores de dividendos Todos os indicadores

Em 2022, Moderna Inc. já distribuiu € 0,17 em dividendos. A última distribuição ocorreu em maio de 2022.

Dados financeiros da empresa

No último trimestre, Moderna Inc. registou receitas de € 127,05 mi e um ganho líquido de -€ 685,2 mi

(EUR)	junho de 2026	YoY
Receitas	127,05 mi	5,46%
Ganho bruto	45,56 mi	133,49%
Ganho líquido	-685,2 mi	2,11%
EBITDA	-616,85 mi	4,33%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 46,39 bi
Número de ações	396,79 mi
Máximo/mínimo de 52 semanas	€ 152,31 - € 19,21
Dividendos	Não
Beta	0,90
PER (PE Ratio)	-16,99
PEG (PEG Ratio)	2,01
P/VC (PB Ratio)	7,94
P/V (PS Ratio)	24,15

Perfil da empresa

Moderna, Inc., ein Biotechnologieunternehmen, entdeckt, entwickelt und vermarktet Boten-RNA-Therapeutika und Impfstoffe zur Behandlung von Infektionskrankheiten, Immunonkologie, seltenen Krankheiten, Herz-Kreislauf-Erkrankungen und Autoimmunerkrankungen in den Vereinigten Staaten, Europa und international. Die Impfstoffe gegen Atemwegserkrankungen umfassen COVID-19, Grippe, Respiratory Syncytial Virus, Endemic HCoV und hMPV+PIV3; die latenten Impfstoffe umfassen Cytomegalovirus, Epstein-Barr-Virus, Humanes Immundefizienz-Virus, Herpes-Simplex-Virus und Varizella-Zoster-Virus; und die Impfstoffe für die öffentliche Gesundheit bestehen aus Zika- und Nipah-Impfstoffen. Das Unternehmen bietet auch systemische sekretorische und Zelloberflächentherapeutika, Krebsimpfstoffe wie personalisierte Krebs-, KRAS- und Checkpoint-Impfstoffe, intratumorale Immuno-Onkologieprodukte, lokalisierte regenerative, systemische intrazelluläre und inhalative pulmonale Therapeutika an. Das Unternehmen unterhält strategische Allianzen mit AstraZeneca PLC, Merck & Co, Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc; Metagenomi, Inc; der Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; und der Bill & Melinda Gates Foundation sowie eine Kooperations- und Lizenzvereinbarung mit Chiesi Farmaceutici S.P.A. Das Unternehmen war früher als Moderna Therapeutics, Inc. bekannt und änderte im August 2018 seinen Namen in Moderna, Inc. Moderna, Inc. wurde im Jahr 2010 gegründet und hat seinen Hauptsitz in Cambridge, Massachusetts.

Nome	Moderna Inc.
CEO	Stéphane Bancel
Sede	Cambridge, ma EUA
Site	investors.modernatx.com/overview/default.aspx
Setor	Cuidados de saúde
Indústria	Biotecnologia
Entrada em bolsa	07/12/2018
Colaboradores	4.700